drugset
drugset / Trial / NCT04565249

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

NCT04565249 ↗

Phase 2 Terminated 6 enrolled Pliant Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19

Timeline

Start
2020-10-22
Primary completion
2021-06-01
Completion
2021-08-02

Outcome

Outcome not reported

Stopped: “Study halted and will not resume; participants are no longer being examined or receiving intervention”

Drugs

EvaluationDrugModalityDoseRoute
Subject bexotegrast Small molecule — —

Indications

COVID-19 acute respiratory distress syndrome